Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimenResearch in context

Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimenResearch in context

Summary: Background: The principal barrier to an HIV cure is the presence of the latent viral reservoir (LVR), which has been understudied in African populations. From 2018 to 2019, Uganda instituted a nationwide rollout of ART consisting of Dolutegravir (DTG) with two NRTI, which replaced the prev...

Full description

Bibliographic Details
Main Authors: Roux-Cil Ferreira, Steven J. Reynolds, Adam A. Capoferri, Owen R. Baker, Erin E. Brown, Ethan Klock, Jernelle Miller, Jun Lai, Sharada Saraf, Charles Kirby, Briana Lynch, Jada Hackman, Sarah N. Gowanlock, Stephen Tomusange, Samiri Jamiru, Aggrey Anok, Taddeo Kityamuweesi, Paul Buule, Daniel Bruno, Craig Martens, Rebecca Rose, Susanna L. Lamers, Ronald M. Galiwango, Art F.Y. Poon, Thomas C. Quinn, Jessica L. Prodger, Andrew D. Redd
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:EBioMedicine
Subjects:
HIV
Uganda
Latent reservoir
Dolutegravir
Integrase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396424000756

Similar Items

Similar Items